At the low doses used for rheumatoid arthritis and other autoimmune conditions, methotrexate does not appear to cause meaningful bone loss on its own. Over three years of follow-up, patients on low-dose methotrexate showed no significant difference in bone mineral density at the hip or spine compared to patients not taking the drug. The picture changes, however, when higher doses are involved or when methotrexate is combined with corticosteroids.
Low-Dose Methotrexate and Bone Density
Most people searching this question are taking methotrexate at weekly doses of 7.5 to 25 mg for conditions like rheumatoid arthritis, psoriatic arthritis, or lupus. At these doses, the evidence is reassuring. A study tracking 133 rheumatoid arthritis patients found that after three years, bone mineral density at the lumbar spine and femoral neck was essentially the same whether patients used methotrexate or not.
A large study of postmenopausal women with rheumatoid arthritis found no statistically significant increase in fracture risk among methotrexate users, with a hazard ratio of 1.1, meaning the fracture rate was nearly identical to that of non-users. Blood markers of bone turnover also stay relatively stable on low-dose methotrexate. After six months of therapy, one study found that a key ratio reflecting the balance between bone breakdown and bone protection actually improved slightly, suggesting the drug may even nudge bone metabolism in a favorable direction.
The Corticosteroid Combination Problem
The one clear warning from the research involves corticosteroids. Patients taking prednisone at 5 mg per day or more alongside methotrexate lost significantly more bone in the lumbar spine than patients taking the same dose of prednisone alone. The difference was striking: an additional 8% loss over three years. If you’re on both medications, bone density monitoring becomes more important.
Interestingly, lab research suggests methotrexate may actually counteract some of the bone damage caused by corticosteroids. In animal models, adding methotrexate to a corticosteroid regimen reduced bone loss compared to the corticosteroid alone. Methotrexate appears to do this by blocking the formation of cells that break down bone, a process that corticosteroids ramp up. This protective effect has been demonstrated in the lab but hasn’t fully translated into clinical observations in humans, where the combination still appears to accelerate spine bone loss.
High-Dose Methotrexate in Cancer Treatment
The story is very different for patients receiving high-dose methotrexate as chemotherapy, particularly children treated for acute lymphoblastic leukemia or bone cancer. At these doses, which can be hundreds of times higher than the weekly pill taken for arthritis, methotrexate can cause a recognized condition called methotrexate osteopathy. It’s defined by three features: bone pain, osteoporosis, and stress fractures.
Between 9% and 13.5% of children treated with high-dose methotrexate for leukemia develop fractures, and up to 12% experience osteonecrosis, where bone tissue dies due to reduced blood supply. These complications don’t only occur during treatment. They can appear afterward and during the maintenance phase of chemotherapy. Children treated for bone cancer (osteosarcoma) show a comparable 9% fracture rate. In the most extreme cases, infants with brain tumors who received very high cumulative doses developed thinning bones, abnormal calcium deposits, and growth disruption in their legs.
For adults receiving high-dose methotrexate for cancer, there is surprisingly little clinical data. The limited evidence suggests bone mineral density and mineral content decrease in a dose-dependent pattern, primarily in areas rich in the spongy interior bone tissue rather than the dense outer shell.
How Methotrexate Affects Bone Cells
Your bones are constantly being remodeled by two types of cells working in opposition. One type builds new bone, the other dissolves old bone. Healthy bones depend on these two processes staying in balance. Methotrexate influences both sides, and the net effect depends largely on the dose.
At high doses, methotrexate pushes bone-building cells toward death and promotes the formation of fat cells in the bone marrow instead. It can also stimulate the cells that break bone down. At low doses used for arthritis, the drug appears to inhibit the signaling that triggers bone-dissolving cell formation. It does this by blocking calcium from flowing into the precursor cells that would otherwise mature into bone-destroying cells. This may partly explain why low-dose methotrexate doesn’t cause the bone loss you might expect from a drug with known skeletal toxicity at higher doses.
Protecting Your Bones on Methotrexate
If you’re on low-dose methotrexate without corticosteroids, the drug itself is unlikely to be a significant threat to your bone density. The underlying inflammatory disease, particularly rheumatoid arthritis, is actually a bigger risk factor for bone loss than the methotrexate used to treat it. Chronic inflammation accelerates bone breakdown on its own, and by controlling that inflammation, methotrexate may indirectly help preserve bone.
Folinic acid, which is routinely given alongside high-dose methotrexate in cancer treatment to reduce toxicity, has shown promise for protecting bones specifically. In animal studies, folinic acid supplementation during chronic methotrexate treatment preserved the structure of growing bone by preventing bone-building cells from dying and suppressing the excess fat cell production and bone-dissolving cell formation that methotrexate triggers. These findings are most relevant to children undergoing chemotherapy, where skeletal growth suppression is a real concern.
For anyone on long-term methotrexate, the standard bone-health basics still apply: adequate calcium and vitamin D intake, weight-bearing exercise, and periodic bone density screening if you have additional risk factors like corticosteroid use, menopause, or a family history of osteoporosis.